Bliss GVS Pharma (BLISSGVS) had a P/E of 41.3× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 17% below their 52-week high. Sales and net profit grew 7.2% and 22% a year over 3 years, with ROCE of 15% and ROE of 12%. It carries very little debt, and its dividend yield is 0.2%. It is a small-cap company with a market cap of ₹6,535 Cr, ranked 38th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 311% over the past year.
- ₹626.10
- ₹635.80
- ₹613.00
- ₹632.45
- 76.2K
Health check
- ReturnsAhead
+311.3% over a year, better than 7 of 7 peers.
- Price tagPricier
P/E 41.3 vs industry 28.7.
- GrowthSteady
Sales +7.2%, profit +22.1% a year over 3 years.
- ProfitabilityAverage
ROCE 15.4% vs peer median 17.9%.
- Balance sheetSolid
Practically debt-free, Piotroski 7 of 9.
- Red flagsNone found
No warning signs in the headline numbers.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹6,535 Cr
- Small cap
- P/E
- 41.3
- Industry 28.7
- Price to book
- 5.45
- Peers 4.99
- Dividend yield
- 0.24%
- ROE
- 11.5%
- Peers 14.7%
- ROCE
- 15.4%
- Peers 17.9%
- Debt to equity
- 0.02
- Debt ₹22 Cr
- EPS (TTM)
- ₹14.87
- Face value ₹1
- OPM (TTM)
- 22.0%
- Net margin 13.5%
- Sales growth
- +28.2%
- Latest quarter vs a year ago
- Profit growth
- +91.7%
- Latest quarter vs a year ago
- Price to sales
- 6.50
- EV/EBITDA 33.1
Strengths and risks
Strengths
- Practically debt-free.
- Quarterly profit up 91.7% on a year ago.
- Quarterly sales up 28.2% on a year ago.
- Positive operating cash flow in each of the last 4 years.
- Promoter stake up from 35.4% to 50.1%.
About Bliss GVS Pharma
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. The company offers anti-diabetic, anti-infective, anti-inflammatory, antifungal, antihemorrhoidal, antimalarial, antiseptic, cardiovascular, dermatological, gastrointestinal, gynaecology, neoro/cns, ophthalmic, otc drugs, respiratory, urology, and supplementary drug products, as well as engages in pain management…
- Headquarters
- Mumbai
- Employees
- 1,033
- Sector
- Healthcare
- ISIN
- INE416D01022
- Website
- blissgvs.com
Price range
- Avg volume (3M)
- 3.4 L
- 1-year return
- plus 311.3%
- From 52-week high
- minus 17.0%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.87% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.30% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.81% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.59% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.93% | minus 6.6% |
| BLISSGVSBliss GVS Pharma | 614.25 | minus 2.88% | 6,535 | 41.3 | 5.45 | 15.4% | 11.5% | 22.0% | 7.2% | 22.1% | 0.24% | plus 311.3% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.59% | 22.8% |
Quarterly results
| ₹ Cr | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|
| 244 | 218 | 257 | 286 | 313 | |
| 201 | 183 | 213 | 209 | 233 | |
| 43.5 | 34.8 | 44.4 | 76.4 | 80.6 | |
| 17.8% | 15.9% | 17.3% | 26.8% | 25.7% | |
| 8.5 | 18.5 | 11.2 | 9.6 | 8.3 | |
| 3 | 1.5 | 2 | 0.6 | 3.3 | |
| 8.3 | 8.3 | 8.7 | 9.9 | 10.5 | |
| – | −2.5 | 0 | – | – | |
| 40.6 | 40.9 | 44.9 | 75.5 | 75.1 | |
| 29.6% | 39.4% | 17.7% | 31.9% | 29.0% | |
| 27.3 | 23.3 | 35.6 | 50.1 | 52.3 | |
| 2.54 | 2.14 | 3.27 | 4.65 | 4.81 |
Profit & loss
- Sales CAGR 3Y
- +7.2%
- Profit CAGR 3Y
- +22.1%
- EPS CAGR 3Y
- +21.3%
- ROE
- 11.5%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 747 | 766 | 802 | 921 | |
| – | +2.5% | +4.7% | +14.8% | |
| 628 | 605 | 675 | 728 | |
| 119 | 161 | 127 | 193 | |
| 16.0% | 21.0% | 15.9% | 20.9% | |
| 10.3 | 26.4 | 34.1 | 62.9 | |
| 3.2 | 5.6 | 6.2 | 3.7 | |
| 18.7 | 26.4 | 29.4 | 33.5 | |
| −1.7 | −38.7 | −0 | −28.7 | |
| 106 | 117 | 126 | 190 | |
| 27.7% | 30.2% | 28.2% | 28.9% | |
| 70.9 | 75.5 | 84.3 | 129 | |
| – | +6.5% | +11.7% | +53.2% | |
| 6.72 | 7.11 | 7.95 | 12.00 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 10.4 | 10.5 | 10.5 | 10.6 | |
| 873 | 957 | 1,040 | 1,182 | |
| 102 | 99.8 | 88.1 | 21.8 | |
| 171 | 145 | 163 | 278 | |
| 1,157 | 1,212 | 1,301 | 1,492 | |
| 389 | 380 | 430 | 460 | |
| 18.6 | 18.8 | 32.7 | 9.4 | |
| 56.9 | 8 | 31.1 | 33.9 | |
| 68.4 | 141 | 141 | 189 | |
| 624 | 664 | 666 | 800 | |
| 1,157 | 1,212 | 1,301 | 1,492 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 34.3 | 103 | 106 | 139 | |
| −7.8 | −83.2 | −75.6 | −38.3 | |
| −24.9 | −20.9 | −30.2 | −89.2 | |
| 1.6 | −1.3 | 0.1 | 11.2 | |
| −93.8 | −28.3 | −76.3 | −56.8 | |
| −59.5 | 74.5 | 29.6 | 81.9 | |
| −5.4 | −5.4 | −5.4 | −10.6 |
Shareholding pattern
- Promoters50.07%
- Public49.93%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 50.07% | 49.93% | plus 15.06 | |
| 30 Jun 2026 | 35.01% | 64.99% | minus 0.35 | |
| 31 Mar 2026 | 35.36% | 64.64% | 0.00 | |
| 31 Dec 2025 | 35.36% | 64.64% | minus 0.03 | |
| 30 Sep 2025 | 35.39% | 64.61% | – |
Major shareholders
Filings & events
News
No recent news coverage found.